Lexicon Pharmaceuticals (NASDAQ:LXRX) Receives Hold Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a report issued on Friday,Benzinga reports.

LXRX has been the topic of a number of other research reports. Leerink Partners set a $6.00 price target on shares of Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $6.00.

Lexicon Pharmaceuticals Trading Down 5.8 %

Shares of Lexicon Pharmaceuticals stock opened at $0.81 on Friday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a 12-month low of $0.73 and a 12-month high of $3.73. The firm has a market capitalization of $200.24 million, a price-to-earnings ratio of -1.08 and a beta of 1.24. The firm’s 50 day simple moving average is $1.51 and its two-hundred day simple moving average is $1.69.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.14 million. During the same quarter in the previous year, the company posted ($0.21) EPS. Analysts predict that Lexicon Pharmaceuticals will post -0.69 EPS for the current year.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in LXRX. FMR LLC boosted its holdings in Lexicon Pharmaceuticals by 28.9% during the third quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after buying an additional 11,179,919 shares in the last quarter. Point72 Asset Management L.P. boosted its holdings in Lexicon Pharmaceuticals by 605.2% during the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock worth $6,924,000 after buying an additional 3,536,805 shares in the last quarter. Nantahala Capital Management LLC purchased a new stake in Lexicon Pharmaceuticals during the second quarter worth $3,871,000. Marshall Wace LLP boosted its holdings in Lexicon Pharmaceuticals by 138.5% during the second quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company’s stock worth $2,000,000 after buying an additional 691,276 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in Lexicon Pharmaceuticals during the second quarter worth $912,000. 74.70% of the stock is owned by hedge funds and other institutional investors.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.